Second Sight Medical is looking to bridge the gap to its forthcoming initial public offering with a $3 million loan from iconic chairman Al Mann.
NeuroSigma aims to reap as much as $50.2 million in its upcoming initial public offering for the UCLA spinout’s noninvasive system to treat drug-resistant epilepsy.
NeuroSigma plans to sell 3.6 million shares on the NASDAQ exchange for between $13 and $15 each, reserving the symbol NSIG, according to a regulatory filing.
EndoStim said it hopes to raise nearly $36 million in an initial public offering, with plans to plow $10 million into clinical studies of its system to treat severe gastroesophageal reflux disease and another $14 million to commercialize the system.
Acutus Medical said it secured $26.2 million in new funding for the cardiac mapping technology it’s developing to image and map atrial fibrillation hotspots.